Terms: = Leukemia AND NPM1, NPM, 4869, ENSG00000181163, P06748, B23, MGC104254 AND Treatment
533 results:
1. Comprehensive Molecular Profiling of npm1-Mutated Acute Myeloid leukemia Using RNAseq Approach.
Petiti J; Pignochino Y; Schiavon A; Giugliano E; Berrino E; Giordano G; Itri F; Dragani M; Cilloni D; Lo Iacono M
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612443
[TBL] [Abstract] [Full Text] [Related]
2. Unlocking the potential: A novel prognostic index signature for acute myeloid leukemia.
Zhang LQ; Liang YC; Wang JX; Zhang J; La T; Li QZ
Comput Biol Med; 2024 May; 173():108396. PubMed ID: 38574529
[TBL] [Abstract] [Full Text] [Related]
3. Regulation of HOX gene expression in AML.
Khan I; Amin MA; Eklund EA; Gartel AL
Blood Cancer J; 2024 Mar; 14(1):42. PubMed ID: 38453907
[TBL] [Abstract] [Full Text] [Related]
4. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.
Fiskus W; Piel J; Collins M; Hentemann M; Cuglievan B; Mill CP; Birdwell CE; Das K; Davis JA; Hou H; Jain A; Malovannaya A; Kadia TM; Daver N; Sasaki K; Takahashi K; Hammond D; Reville PK; Wang J; Loghavi S; Sen R; Ruan X; Su X; Flores LB; DiNardo CD; Bhalla KN
Blood; 2024 May; 143(20):2059-2072. PubMed ID: 38437498
[TBL] [Abstract] [Full Text] [Related]
5. Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses.
Severens JF; Karakaslar EO; van der Reijden BA; Sánchez-López E; van den Berg RR; Halkes CJM; van Balen P; Veelken H; Reinders MJT; Griffioen M; van den Akker EB
Leukemia; 2024 Apr; 38(4):751-761. PubMed ID: 38360865
[TBL] [Abstract] [Full Text] [Related]
6. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Abaza Y; Winer ES; Murthy GSG; Shallis RM; Matthews AH; Badar T; Geramita EM; Kota VK; Swaroop A; Doukas P; Bradshaw D; Helenowski IB; Liu Y; Zhang H; Im A; Litzow MR; Perl AE; Atallah E; Altman JK
Am J Hematol; 2024 Apr; 99(4):606-614. PubMed ID: 38342997
[TBL] [Abstract] [Full Text] [Related]
7. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
[TBL] [Abstract] [Full Text] [Related]
8. Development of a risk assessment model for cardiac injury in patients newly diagnosed with acute myeloid leukemia based on a multicenter, real-world analysis in China.
Ma L; Wang Q; Li X; Shang Y; Zhang N; Wu J; Liang Y; Chen G; Tan Y; Liu X; Yuan G; Zhou F
BMC Cancer; 2024 Jan; 24(1):132. PubMed ID: 38273254
[TBL] [Abstract] [Full Text] [Related]
9. Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
Didi I; Alliot JM; Dumas PY; Vergez F; Tavitian S; Largeaud L; Bidet A; Rieu JB; Luquet I; Lechevalier N; Delabesse E; Sarry A; De Grande AC; Bérard E; Pigneux A; Récher C; Simoncini D; Bertoli S
Leuk Res; 2024 Jan; 136():107437. PubMed ID: 38215555
[TBL] [Abstract] [Full Text] [Related]
10. Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance.
Mishra R; Zokaei Nikoo M; Veeraballi S; Singh A
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203655
[TBL] [Abstract] [Full Text] [Related]
11. Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia.
Cui J; Chen X; Li C; Yan Q; Yuan G
Hematology; 2024 Dec; 29(1):2293512. PubMed ID: 38095287
[TBL] [Abstract] [Full Text] [Related]
12. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Gangat N; Karrar O; Iftikhar M; McCullough K; Johnson IM; Abdelmagid M; Abdallah M; Al-Kali A; Alkhateeb HB; Begna KH; Mangaonkar A; Saliba AN; Hefazi Torghabeh M; Litzow MR; Hogan W; Shah M; Patnaik MM; Pardanani A; Badar T; Murthy H; Foran J; Palmer J; Sproat L; Khera N; Arana Yi C; Tefferi A
Am J Hematol; 2024 Feb; 99(2):193-202. PubMed ID: 38071734
[TBL] [Abstract] [Full Text] [Related]
13. [Efficacy and Survival of Venetoclax Based Regimen in the treatment of Acute Myeloid leukemia].
Kong FC; Qi L; Huang WF; Yu M; Zhou YL; Ji DX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1676-1683. PubMed ID: 38071045
[TBL] [Abstract] [Full Text] [Related]
14. Understanding differential technologies for detection of MRD and how to incorporate into clinical practice.
Cloos J; Ngai LL; Heuser M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):682-690. PubMed ID: 38066915
[TBL] [Abstract] [Full Text] [Related]
15. Venetoclax-based low intensity therapy in molecular failure of npm1-mutated AML.
Jimenez-Chillon C; Othman J; Taussig D; Jimenez-Vicente C; Martinez-Roca A; Tiong IS; Jain M; Aries J; Cakmak S; Knapper S; Kristensen DT; Murthy V; Galani JZ; Kallmeyer C; Ngu L; Veale D; Bolam S; Orfali N; Parker A; Manson C; Parker J; Erblich T; Richardson D; Mokretar K; Potter N; Overgaard UM; Roug AS; Wei AH; Esteve J; Jädersten M; Russell N; Dillon R
Blood Adv; 2024 Jan; 8(2):343-352. PubMed ID: 38039513
[TBL] [Abstract] [Full Text] [Related]
16. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid leukemia.
Blackmon AL; Hourigan CS
Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
[TBL] [Abstract] [Full Text] [Related]
17. The ferroptosis landscape in acute myeloid leukemia.
Ma Z; Ye W; Huang X; Li X; Li F; Lin X; Hu C; Wang J; Jin J; Zhu B; Huang J
Aging (Albany NY); 2023 Nov; 15(22):13486-13503. PubMed ID: 38032290
[TBL] [Abstract] [Full Text] [Related]
18. Clinical significance of WT1 in the evaluation of therapeutic effect and prognosis of non-M3 acute myeloid leukemia.
Yu T; Zhan Q; Yan X; Luo X; Wang X; Tang X; Zhang H; Yang Z; Chen J; Liu L; Wang L
Cancer Biol Ther; 2023 Dec; 24(1):2285801. PubMed ID: 38031921
[TBL] [Abstract] [Full Text] [Related]
19. Proteomics analysis identifies the ribosome associated coiled-coil domain-containing protein-124 as a novel interaction partner of nucleophosmin-1.
Çakırca G; Öztürk MT; Telkoparan-Akillilar P; Güllülü Ö; Çetinkaya A; Tazebay UH
Biol Cell; 2024 Jan; 116(1):e202300049. PubMed ID: 38029384
[TBL] [Abstract] [Full Text] [Related]
20. The future of HOXA- expressing leukemias: Menin inhibitor response and resistance.
Wenge DV; Armstrong SA
Curr Opin Hematol; 2024 Mar; 31(2):64-70. PubMed ID: 38010951
[TBL] [Abstract] [Full Text] [Related]
[Next]
